

General description

INN	Didanosine
ATC codes	J05AF02
Medicine type	Chemical agent
EML status history	First added in 2002 (TRS 914) for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Removed in 2015 (TRS 994) for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Wikipedia	Didanosine ↗
DrugBank	Didanosine ↗

Recommendations

Section Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution

Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

